메뉴 건너뛰기




Volumn 87, Issue 1, 2012, Pages 25-33

One thousand patients with primary myelofibrosis: The Mayo Clinic experience

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

EID: 84855656900     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2011.11.001     Document Type: Article
Times cited : (190)

References (53)
  • 1
    • 70349256226 scopus 로고    scopus 로고
    • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
    • Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
    • (2009) Blood , vol.114 , Issue.5 , pp. 937-951
    • Vardiman, J.W.1    Thiele, J.2    Arber, D.A.3
  • 3
    • 34447610836 scopus 로고
    • Zwei Falle von Leukamie mit eigenthumlichem Blutresp. Knochenmarksbefund
    • Heuck G. Zwei Falle von Leukamie mit eigenthumlichem Blutresp. Knochenmarksbefund [Two cases of leukemia with peculiar blood and bone marrow findings, respectively]. Arch Pathol Anat Physiol Virchows. 1879;78:475-496.
    • (1879) Arch Pathol Anat Physiol Virchows , vol.78 , pp. 475-496
    • Heuck, G.1
  • 4
    • 0001639195 scopus 로고
    • Some speculations on the myeloproliferative syndromes
    • Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375.
    • (1951) Blood , vol.6 , pp. 372-375
    • Dameshek, W.1
  • 5
    • 0017812507 scopus 로고
    • Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis
    • Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51(2):189-194. (Pubitemid 8284647)
    • (1978) Blood , vol.51 , Issue.2 , pp. 189-194
    • Jacobson, R.J.1    Salo, A.2    Fialkow, P.J.3
  • 6
    • 38349060667 scopus 로고    scopus 로고
    • The history of myeloproliferative disorders: Before and after Dameshek
    • Tefferi A. The history of myeloproliferative disorders: before and after Dameshek. Leukemia. 2008;22(1):3-13.
    • (2008) Leukemia , vol.22 , Issue.1 , pp. 3-13
    • Tefferi, A.1
  • 9
    • 72849159485 scopus 로고
    • Chromosome studies on normal and leukemic human leukocytes
    • July
    • Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960 July; 25:85-109.
    • (1960) J Natl Cancer Inst , vol.25 , pp. 85-109
    • Nowell, P.C.1    Hungerford, D.A.2
  • 10
    • 0021802841 scopus 로고
    • Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
    • DOI 10.1038/315550a0
    • Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315(6020):550-554. (Pubitemid 15021190)
    • (1985) Nature , vol.315 , Issue.6020 , pp. 550-554
    • Shtivelman, E.1    Lifshitz, B.2    Gale, R.P.3    Canaani, E.4
  • 11
    • 0022352068 scopus 로고
    • Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome
    • Stam K, Heisterkamp N, Grosveld G, et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med. 1985;313(23):1429-1433. (Pubitemid 16212323)
    • (1985) New England Journal of Medicine , vol.313 , Issue.23 , pp. 1429-1433
    • Stam, K.1    Heisterkamp, N.2    Grosveld, G.3
  • 12
    • 0025187837 scopus 로고
    • Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
    • Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87(17):6649-6653.
    • (1990) Proc Natl Acad Sci U S A , vol.87 , Issue.17 , pp. 6649-6653
    • Kelliher, M.A.1    McLaughlin, J.2    Witte, O.N.3    Rosenberg, N.4
  • 13
    • 0025117392 scopus 로고
    • Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
    • Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824-830.
    • (1990) Science , vol.247 , Issue.4944 , pp. 824-830
    • Daley, G.Q.1    Van Etten, R.A.2    Baltimore, D.3
  • 14
    • 0025271543 scopus 로고
    • Bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
    • Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. Embo J. 1990;9(4):1069-1078.
    • (1990) Embo J , vol.9 , Issue.4 , pp. 1069-1078
    • Elefanty, A.G.1    Hariharan, I.K.2    Cory, S.3
  • 15
    • 38349101871 scopus 로고    scopus 로고
    • Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
    • Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
    • (2008) Leukemia , vol.22 , Issue.1 , pp. 14-22
    • Tefferi, A.1    Vardiman, J.W.2
  • 16
    • 77954581139 scopus 로고    scopus 로고
    • Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
    • Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-1138.
    • (2010) Leukemia , vol.24 , Issue.6 , pp. 1128-1138
    • Tefferi, A.1
  • 17
    • 84860739723 scopus 로고    scopus 로고
    • SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients
    • In press
    • Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2011. In press.
    • (2011) Leukemia
    • Lasho, T.L.1    Finke, C.M.2    Hanson, C.A.3
  • 19
    • 79960248721 scopus 로고    scopus 로고
    • DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
    • Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. 2011;25(7):1219-1220.
    • (2011) Leukemia , vol.25 , Issue.7 , pp. 1219-1220
    • Abdel-Wahab, O.1    Pardanani, A.2    Rampal, R.3    Lasho, T.L.4    Levine, R.L.5    Tefferi, A.6
  • 21
    • 79952087335 scopus 로고    scopus 로고
    • DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status
    • Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
    • (2011) J Clin Oncol , vol.29 , Issue.4 , pp. 392-397
    • Gangat, N.1    Caramazza, D.2    Vaidya, R.3
  • 22
    • 79953711716 scopus 로고    scopus 로고
    • How I treat myelofibrosis
    • Tefferi A. How I treat myelofibrosis. Blood. 2011;117(13):3494-3504.
    • (2011) Blood , vol.117 , Issue.13 , pp. 3494-3504
    • Tefferi, A.1
  • 24
    • 77956696835 scopus 로고    scopus 로고
    • Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
    • Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
    • (2010) N Engl J Med , vol.363 , Issue.12 , pp. 1117-1127
    • Verstovsek, S.1    Kantarjian, H.2    Mesa, R.A.3
  • 25
    • 79952333359 scopus 로고    scopus 로고
    • Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
    • Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-796.
    • (2011) J Clin Oncol , vol.29 , Issue.7 , pp. 789-796
    • Pardanani, A.1    Gotlib, J.R.2    Jamieson, C.3
  • 26
    • 42449124578 scopus 로고    scopus 로고
    • Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
    • DOI 10.1038/sj.leu.2405097, PII 2405097
    • Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22(4):756-761. (Pubitemid 351559282)
    • (2008) Leukemia , vol.22 , Issue.4 , pp. 756-761
    • Tefferi, A.1    Lasho, T.L.2    Huang, J.3    Finke, C.4    Mesa, R.A.5    Li, C.Y.6    Wu, W.7    Hanson, C.A.8    Pardanani, A.9
  • 27
    • 33750534561 scopus 로고    scopus 로고
    • MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients
    • Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
    • (2006) Blood , vol.108 , Issue.10 , pp. 3472-3476
    • Pardanani, A.D.1    Levine, R.L.2    Lasho, T.3
  • 28
    • 67349145955 scopus 로고    scopus 로고
    • Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates
    • Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23(5):900-904.
    • (2009) Leukemia , vol.23 , Issue.5 , pp. 900-904
    • Tefferi, A.1    Levine, R.L.2    Lim, K.H.3
  • 29
    • 74249123815 scopus 로고    scopus 로고
    • JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
    • Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010;24(1):105-109.
    • (2010) Leukemia , vol.24 , Issue.1 , pp. 105-109
    • Tefferi, A.1    Lasho, T.L.2    Patnaik, M.M.3
  • 30
    • 77954658823 scopus 로고    scopus 로고
    • IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
    • Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24(7):1302-1309.
    • (2010) Leukemia , vol.24 , Issue.7 , pp. 1302-1309
    • Tefferi, A.1    Lasho, T.L.2    Abdel-Wahab, O.3
  • 31
    • 78651344350 scopus 로고    scopus 로고
    • Refined cytogeneticrisk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients
    • Caramazza D, Begna KH, Gangat N, et al. Refined cytogeneticrisk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82-88.
    • (2011) Leukemia , vol.25 , Issue.1 , pp. 82-88
    • Caramazza, D.1    Begna, K.H.2    Gangat, N.3
  • 32
    • 63849328927 scopus 로고    scopus 로고
    • New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    • Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
    • (2009) Blood , vol.113 , Issue.13 , pp. 2895-2901
    • Cervantes, F.1    Dupriez, B.2    Pereira, A.3
  • 33
    • 77950352432 scopus 로고    scopus 로고
    • A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
    • Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
    • (2010) Blood , vol.115 , Issue.9 , pp. 1703-1708
    • Passamonti, F.1    Cervantes, F.2    Vannucchi, A.M.3
  • 34
    • 0032916213 scopus 로고    scopus 로고
    • Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An olmsted county study, 1976-1995
    • DOI 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I
    • Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999;61(1):10-15. (Pubitemid 29218171)
    • (1999) American Journal of Hematology , vol.61 , Issue.1 , pp. 10-15
    • Mesa, R.A.1    Silverstein, M.N.2    Jacobsen, S.J.3    Wollan, P.C.4    Tefferi, A.5
  • 35
    • 80054028202 scopus 로고    scopus 로고
    • Long-term outcome of ruxolitinib therapy in myelofibrosis
    • Tefferi A, Litzow MR, Pardanani A. Long-term outcome of ruxolitinib therapy in myelofibrosis. N Engl J Med. 2011;365(15):1455-1457.
    • (2011) N Engl J Med , vol.365 , Issue.15 , pp. 1455-1457
    • Tefferi, A.1    Litzow, M.R.2    Pardanani, A.3
  • 36
    • 84900620388 scopus 로고    scopus 로고
    • Long-term outcome of pomalidomide therapy in myelofibrosis
    • In press
    • Begna KH, Pardanani A, Mesa RA, et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Blood. 2011. In press.
    • (2011) Blood
    • Begna, K.H.1    Pardanani, A.2    Mesa, R.A.3
  • 37
    • 71949121402 scopus 로고    scopus 로고
    • Pomalidomide is active in the treatment of anemia associated with myelofibrosis
    • Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563-4569.
    • (2009) J Clin Oncol , vol.27 , Issue.27 , pp. 4563-4569
    • Tefferi, A.1    Verstovsek, S.2    Barosi, G.3
  • 38
    • 79751528798 scopus 로고    scopus 로고
    • A phase-2 trial of low-dose pomalidomide in myelofibrosis
    • Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011;25(2):301-304.
    • (2011) Leukemia , vol.25 , Issue.2 , pp. 301-304
    • Begna, K.H.1    Mesa, R.A.2    Pardanani, A.3
  • 39
    • 15644380236 scopus 로고    scopus 로고
    • Long-term survival of patients with acute myeloid leukemia: A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia
    • Bloomfield CD, Shuma C, Regal L, et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer. 1997;80(11, suppl):2191-2198.
    • (1997) Cancer , vol.80 , Issue.11 SUPPL. , pp. 2191-2198
    • Bloomfield, C.D.1    Shuma, C.2    Regal, L.3
  • 41
    • 80055075486 scopus 로고    scopus 로고
    • Predictors of greater than 80% 2-year mortality in primary myelofibrosis: A Mayo Clinic study of 884 karyotypically-annotated patients
    • Tefferi A, Jimma T, Gangat N, et al. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically-annotated patients. Blood. 2011;118(17):4595-4598.
    • (2011) Blood , vol.118 , Issue.17 , pp. 4595-4598
    • Tefferi, A.1    Jimma, T.2    Gangat, N.3
  • 42
    • 79957625402 scopus 로고    scopus 로고
    • Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival
    • Vaidya R, Caramazza D, Begna KH, et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011;117(21):5612-5615.
    • (2011) Blood , vol.117 , Issue.21 , pp. 5612-5615
    • Vaidya, R.1    Caramazza, D.2    Begna, K.H.3
  • 43
    • 77449126735 scopus 로고    scopus 로고
    • International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
    • Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115(3):496-499.
    • (2010) Blood , vol.115 , Issue.3 , pp. 496-499
    • Hussein, K.1    Pardanani, A.D.2    Van Dyke, D.L.3    Hanson, C.A.4    Tefferi, A.5
  • 44
    • 61349116698 scopus 로고    scopus 로고
    • Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
    • Hussein K, Huang J, Lasho T, et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol. 2009;82(4):255-259.
    • (2009) Eur J Haematol , vol.82 , Issue.4 , pp. 255-259
    • Hussein, K.1    Huang, J.2    Lasho, T.3
  • 45
    • 34248340834 scopus 로고    scopus 로고
    • Validation and comparison of contemporary prognostic models in primary myelofibrosis: Analysis based on 334 patients from a single institution
    • DOI 10.1002/cncr.22630
    • Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 2007;109(10):2083-2088. (Pubitemid 46744203)
    • (2007) Cancer , vol.109 , Issue.10 , pp. 2083-2088
    • Tefferi, A.1    Huang, J.2    Schwager, S.3    Li, C.-Y.4    Wu, W.5    Pardanani, A.6    Mesa, R.A.7
  • 46
    • 74049116496 scopus 로고    scopus 로고
    • Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival
    • Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol. 2010;84(2):105-108.
    • (2010) Eur J Haematol , vol.84 , Issue.2 , pp. 105-108
    • Patnaik, M.M.1    Caramazza, D.2    Gangat, N.3    Hanson, C.A.4    Pardanani, A.5    Tefferi, A.6
  • 47
    • 65649110882 scopus 로고    scopus 로고
    • Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis - Increased serum ferritin or transfusion load does not
    • Tefferi A, Mesa RA, Pardanani A, et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis - increased serum ferritin or transfusion load does not. Am J Hematol. 2009;84(5):265-267.
    • (2009) Am J Hematol , vol.84 , Issue.5 , pp. 265-267
    • Tefferi, A.1    Mesa, R.A.2    Pardanani, A.3
  • 48
    • 81055126771 scopus 로고    scopus 로고
    • EZH2 mutational status predicts poor survival in myelofibrosis
    • Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011;118(19):5227-5234.
    • (2011) Blood , vol.118 , Issue.19 , pp. 5227-5234
    • Guglielmelli, P.1    Biamonte, F.2    Score, J.3
  • 49
    • 84857993923 scopus 로고    scopus 로고
    • IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: Clinical evidence for leukemogenic collaboration with JAK2V617F
    • In press
    • Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2011. In press.
    • (2011) Leukemia
    • Tefferi, A.1    Jimma, T.2    Sulai, N.H.3
  • 50
    • 79954433836 scopus 로고    scopus 로고
    • Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study
    • Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-1363.
    • (2011) J Clin Oncol , vol.29 , Issue.10 , pp. 1356-1363
    • Tefferi, A.1    Vaidya, R.2    Caramazza, D.3    Finke, C.4    Lasho, T.5    Pardanani, A.6
  • 51
    • 84900645349 scopus 로고    scopus 로고
    • IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
    • In press
    • Pardanani A, Finke C, Lasho TL, et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia. 2011. In press.
    • (2011) Leukemia
    • Pardanani, A.1    Finke, C.2    Lasho, T.L.3
  • 52
    • 79953045011 scopus 로고    scopus 로고
    • Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis
    • Pardanani A, Begna K, Finke C, Lasho T, Tefferi A. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol. 2011;86(4):343-345.
    • (2011) Am J Hematol , vol.86 , Issue.4 , pp. 343-345
    • Pardanani, A.1    Begna, K.2    Finke, C.3    Lasho, T.4    Tefferi, A.5
  • 53
    • 79751531643 scopus 로고    scopus 로고
    • Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype
    • Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia. 2011;25(2):266-270.
    • (2011) Leukemia , vol.25 , Issue.2 , pp. 266-270
    • Patnaik, M.M.1    Hanson, C.A.2    Hodnefield, J.M.3    Knudson, R.4    Van Dyke, D.L.5    Tefferi, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.